Physician profile
Steven D Reinglass
NPI 1063549194
$2,010.73
in general payments reported to CMS, 2019-2025
22 companies · $89.65 in 2025
The $89.65 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $128 · 2021: $199 · 2022: $208 · 2023: $140 · 2024: $89.88 · 2025: $89.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.83 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,154.35 | 2019-2025 | Rocklatan, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.49 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $88.58 | 2020-2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $72.03 | 2021-2023 | |
| Aerie Pharmaceuticals, INC. | $66.80 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $61.17 | 2022-2024 | Miebo |
| Sun Pharmaceutical Industries INC. | $58.47 | 2020-2023 | Cequa |
| Allergan, INC. | $53.27 | 2020-2022 | |
| Oyster Point Pharma, INC. | $51.83 | 2022-2024 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Thea Pharma INC. | $36.49 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $28.77 | 2024 | Vevye |
| Dompe US, INC. | $21.94 | 2022 | |
| Abbvie INC. | $20.30 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $19.87 | 2024 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $19.63 | 2022 | |
| Akorn Operating Company LLC | $17.71 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Biotissue Holdings INC. | $15.31 | 2021 | |
| Genentech USA, INC. | $15.03 | 2022 | |
| Shire North American Group INC | $14.50 | 2019 | |
| Glaukos Corporation | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Reinglass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.